Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase

ABSTRACT: Objectives: Sotrovimab effectively prevented progression to severe disease and mortality following infection with pre-Omicron SARS-CoV-2 variants. We sought to determine whether sotrovimab is similarly effective against SARS-CoV-2 Omicron variant infection. Methods: Observational cohort s...

Full description

Bibliographic Details
Main Authors: Neil R. Aggarwal, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Kyle C. Molina, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Adit A. Ginde
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:International Journal of Infectious Diseases
Subjects:
Real-world evidence
Monoclonal antibody
COVID-19
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971222005409

Internet

http://www.sciencedirect.com/science/article/pii/S1201971222005409

Similar Items